103.29

1.71% -2.14

Nuvalent Inc (NUVL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NUVL? Forum Prognose

Schlusskurs vom Vortag:

$105.43

Offen:

$104.28

24-Stunden-Volumen:

617.73K

Relative Volume:

1.10

Marktkapitalisierung:

$8.12B

Einnahmen:

Nettoeinkommen (Verlust:

$-425.38M

KGV:

-17.66

EPS:

-5.8504

Netto-Cashflow:

$-275.21M

1W Leistung:

+7.14%

1M Leistung:

+4.24%

6M Leistung:

+23.59%

1J Leistung:

+57.63%

1-Tages-Spanne:

$102.52

$105.86

1-Wochen-Bereich:

$98.73

$106.90

52-Wochen-Spanne:

$55.53

$113.02

Nuvalent Inc Stock (NUVL) Company Profile

Firmenname

Nuvalent Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

508-446-2272

Adresse

ONE BROADWAY, 14TH FLOOR, CAMBRIDGE

Mitarbeiter

228

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NUVL's Discussions on Twitter

Compare NUVL vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NUVL Nuvalent Inc	103.33	8.29B	0	-425.38M	-275.21M	-5.8504
VRTX Vertex Pharmaceuticals Inc	433.56	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.84	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.14	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.59	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.86	35.01B	606.42M	-1.28B	-997.58M	-6.403

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-24	Eingeleitet	Truist	Buy
2025-11-12	Eingeleitet	Canaccord Genuity	Buy
2025-10-16	Fortgesetzt	Stifel	Buy
2025-10-15	Eingeleitet	Cantor Fitzgerald	Overweight
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-09-03	Eingeleitet	Raymond James	Outperform
2025-08-19	Eingeleitet	Piper Sandler	Overweight
2025-03-14	Hochstufung	UBS	Neutral → Buy
2024-12-30	Eingeleitet	H.C. Wainwright	Buy
2024-10-24	Eingeleitet	UBS	Neutral
2024-08-29	Eingeleitet	Barclays	Overweight
2024-04-17	Eingeleitet	Jefferies	Buy
2024-04-01	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-02-28	Fortgesetzt	Guggenheim	Buy
2024-02-23	Eingeleitet	Robert W. Baird	Outperform
2023-09-27	Eingeleitet	Stifel	Buy
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-24	Eingeleitet	Guggenheim	Buy
2023-01-18	Eingeleitet	Wedbush	Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform

Alle ansehen

Nuvalent Inc Aktie (NUVL) Neueste Nachrichten

Apr 04, 2026

Nuvalent (NUVL) CFO sells 11,430 shares after option exercise under 10b5-1 plan - Stock Titan

Apr 03, 2026

Apr 02, 2026

[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan

Apr 02, 2026

Wells Fargo Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $116 - Moomoo

Apr 02, 2026

Apr 01, 2026

Nuvalent Insider Sold Shares Worth $537,943, According to a Recent SEC Filing - marketscreener.com

Apr 01, 2026

Nuvalent (NUVL) CDO exercises options, sells 5,500 shares under 10b5-1 plan - Stock Titan

Apr 01, 2026

Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation - MSN

Apr 01, 2026

Mar 31, 2026

Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $135 - moomoo.com

Mar 31, 2026

Price-Driven Insight from (NUVL) for Rule-Based Strategy - news.stocktradersdaily.com

Mar 31, 2026

Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch - au.investing.com

Mar 31, 2026

Mar 30, 2026

22,000 Class A shares proposed sale — NUVL (NASDAQ: NUVL) - Stock Titan

Mar 30, 2026

Nuvalent Insider Sold Shares Worth $542,991, According to a Recent SEC Filing - marketscreener.com

Mar 30, 2026

Nuvalent (NUVL) CLO exercises 5.5K options, sells 5.5K shares under 10b5-1 - Stock Titan

Mar 30, 2026

Nuvalent Initiated at Overweight by Wells Fargo - Moomoo

Mar 30, 2026

Wells Fargo initiates Nuvalent stock with overweight rating on drug potential By Investing.com - in.investing.com

Mar 30, 2026

Wells Fargo initiates Nuvalent stock with overweight rating on drug potential - Investing.com Canada

Mar 30, 2026

Nuvalent (NASDAQ:NUVL) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat

Mar 30, 2026

Wells Fargo Initiates Nuvalent at Overweight With $116 Price Target - marketscreener.com

Mar 30, 2026

Wells Fargo Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $116 - Moomoo

Mar 30, 2026

Wells Fargo initiates coverage of Nuvalent (NUVL) with overweight recommendation - MSN

Mar 30, 2026

Mar 29, 2026

Upcoming AACR 2026 event announcement sees Nuvalent stock down 1.43% - Traders Union

Mar 29, 2026

Mar 27, 2026

Weekly Trades: Should I set a stop loss on Nuvalent IncQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn

Mar 27, 2026

Vanguard disaggregates holdings after realignment; Nuvalent (NUVL) ownership listed as 0 - Stock Titan

Mar 27, 2026

Mar 26, 2026

Nuvalent (NUVL) CFO sells 25,130 shares in Rule 10b5-1 trades - Stock Titan

Mar 26, 2026

S&P 500 Futures Drop in Premarket Trading; Nuvalent, Figure Tech Solns Lead - Barron's

Mar 26, 2026

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail

Mar 26, 2026

Mar 24, 2026

NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan

Mar 24, 2026

Mar 23, 2026

ALK-Positive NSCLC Pipeline Gains Momentum as 6+ Pharma Companies Advance Next-Generation Therapies | DelveInsight - Barchart.com

Mar 23, 2026

Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today

Mar 23, 2026

Hudson Bay Capital Management LP Purchases New Stake in Nuvalent, Inc. $NUVL - MarketBeat

Mar 23, 2026

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - AOL.com

Mar 23, 2026

Mar 22, 2026

Trend Report: Is Nuvalent Inc in a consolidation phase2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn

Mar 22, 2026

Aug Catalysts: Is Nuvalent Inc in a consolidation phase2026 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn

Mar 22, 2026

Mar 20, 2026

Nuvalent (NUVL) officer Benjamin Lane details stock, options and RSUs in Form 3 - Stock Titan

Mar 20, 2026

(NUVL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Mar 20, 2026

Mar 19, 2026

FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL) - Yahoo Finance

Mar 19, 2026

Cantor Fitzgerald L. P. Makes New $1.95 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat

Mar 19, 2026

Mar 18, 2026

Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN

Mar 18, 2026

Mar 17, 2026

Nuvalent to Present New Preclinical and Clinical Data for Zidesa - GuruFocus

Mar 17, 2026

Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026 - Traders Union

Mar 17, 2026

Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - StreetInsider

Mar 17, 2026

Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company OutlookNews and Statistics - IndexBox

Mar 17, 2026

Nuvalent (NUVL) Gets a Buy from Canaccord Genuity - The Globe and Mail

Mar 17, 2026

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Mar 17, 2026

Mar 16, 2026

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool

Mar 16, 2026

Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares - TradingView

Mar 16, 2026

Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises - Stock Titan

Mar 16, 2026

Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC - National Today

Mar 16, 2026